KFI
LXEO icon

Key Financial Inc’s Lexeo Therapeutics LXEO Stock Holding History

Key Financial Inc’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$931 Hold
200
– – ﹤0.01% 1221
2026
Q1 		$1.15K Buy
+200
New +$1.42K ﹤0.01% 1237

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Key Financial Inc's LXEO Position: Q2 2026 in Review

Key Financial Inc held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 200 shares worth $931. The position accounts for ﹤0.01% of the portfolio, ranked #1221.

Key Financial Inc first reported a position in LXEO in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.15K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Key Financial Inc held 200 shares of Lexeo Therapeutics worth $931 as of Q2 2026.
  • Key Financial Inc left its Lexeo Therapeutics share count unchanged in Q2 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Key Financial Inc's portfolio in Q2 2026, its #1221 holding.
  • Key Financial Inc first reported a position in Lexeo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Key Financial Inc's Lexeo Therapeutics position peaked at $1.15K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Key Financial Inc's 13F filing for Q2 2026, filed 24 Jul 2026.